Abstract 719TiP
Background
HRO761 is a first-in-class selective WRN inhibitor that binds allosterically to the helicase domain of the WRN protein locking it in an inactive conformation. HRO761 has shown anti-tumor activity in MSIhi preclinical models.
Trial design
This is a phase I/Ib (NCT05838768), global, multicenter (approximately 27 sites to open across 14 countries) dose finding study that consists of a dose escalation part to allow the determination of a dose range for optimization (DRO) or a recommended dose (RD) for HRO761 single agent (s.a.), and an optional randomized dose optimization part (Arm A). HRO761 will be administered orally daily in a 28-day cycle. The dose escalation part will enroll MSIhi/dMMR advanced/metastatic (a/m) CRC and solid tumors (approximately 40 patients), and the randomized dose optimization part will enroll patients with a/m MSIhi /dMMR CRC (20 patients per dose) and solid tumors (up to 10 pts per dose). Based on an integrated analysis of the safety, tolerability, pharmacokinetic, pharmacodynamic, and preliminary anti-tumor activity data of HRO761, RD will be determined and subsequently tested in optional expansion arms of a/m MSIhi/dMMR CRC (20-40 patients), and solid tumor (20-40 patients). HRO761 at the RD will be investigated in a dose escalation in combination with either tislelizumab (Arm B) or irinotecan (Arm C) to determine the RD of the combinations. After the determination of the RDs, the combination treatments will be tested in expansion cohorts of a/m MSIhi or dMMR CRC and other solid tumors. AEs will be assessed according to CTCAE v5. Tumor response will be determined according to RECIST 1.1 criteria. Key eligibility criteria include: 1) Patients with advanced unresectable or metastatic MSIhi or dMMR solid tumors who have progressed after or are intolerant to prior standard therapy; 2) patients should have received at least one prior line of chemotherapy or targeted therapy, and prior immune checkpoint inhibitor therapy (Arm A and C). Checkpoint inhibitor therapy is permitted but not required and prior adjuvant therapy is allowed in Arm B.
Clinical trial identification
NCT05838768, First posted 3 May 2023.
Editorial acknowledgement
None to declare
Legal entity responsible for the study
Novartis Pharmaceuticals.
Funding
Novartis Pharmaceuticals.
Disclosure
M. Moschetta, H. Möbitz, I. Jaco, M. Cortes Cros, S. Ferretti, D. Jankovic, M. Thérier, G. Clementi, Y. Li, R. De Kanter, C. Quadt: Financial Interests, Personal, Stocks/Shares: Novartis; Financial Interests, Personal, Full or part-time Employment: Novartis. T. Doi: Financial Interests, Institutional, Research Grant: Taiho, MSD, AbbVie, Eisai, Pfizer, BMS, Janssen Pharma, Daiichi Sankyo, Chugai Pharma, Boehringer Ingelheim, PRA Health Sciences, Amgen, GSK, SHIONOGI, RIN Institute, ONO Pharma; Financial Interests, Personal, Advisory Role: Noile-Immune Biotech, Oncolys BioPharma, Boehringer Ingelheim, A2 Healthcare, Nano Carrier, PRA Health Sciences, KAKEN Pharma, Chugai Pharma, Sumitomo Pharma, Shionogi, Otsuka Pharma, Takeda, Kyowa Kirin, Rakuten Medical, Gilead; Financial Interests, Personal, Invited Speaker: Daiichi Sankyo. Y. Kuboki: Financial Interests, Institutional, Research Grant: Taiho, Astellas, Eli Lilly, Takeda, Daiichi Sankyo, AstraZeneca, Boehringer Ingelheim, Chugai, Genmab, Incyte, AbbVie, Amgen, Merk ; Financial Interests, Personal, Advisory Role: Incyte, Takeda, Boehringer Ingelheim, Amgen; Financial Interests, Personal, Speaker, Consultant, Advisor: Taiho, Eli Lilly, Takeda. R. Sundar: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Merck, Eisai, Bayer, Taiho, Novartis, MSD, GSK, DKSH, Astellas; Financial Interests, Personal, Invited Speaker: MSD, Eli Lilly, BMS, Roche, Taiho, AstraZeneca, DKSH, Ipsen; Financial Interests, Personal, Stocks/Shares: Teladoc; Financial Interests, Institutional, Advisory Board: Paxman Coolers; Financial Interests, Personal and Institutional, Local PI: Taiho, MSD, BMS, Novartis; Non-Financial Interests, Advisory Role: Paxman Coolers; Non-Financial Interests, Principal Investigator: MSD, Natera.
Resources from the same session
699P - Immunogenicity and reactogenicity of BNT162b2 COVID-19 mRNA vaccine in long-survivor (LS) patients with metastatic lung cancer (mLC) after primary immunization (PV) and booster (BD): COVALENCE study
Presenter: Emanuele Vita
Session: Poster session 17
700P - First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors
Presenter: Adam Cooper
Session: Poster session 17
701P - NCI10221: Phase II multicenter biomarker driven combination trial of copanlisib and nivolumab in patients with molecularly-selected advanced solid tumors (BaCoN)
Presenter: Timothy Yap
Session: Poster session 17
702P - Characterization of germline HLA genotypes in patients (pts) with solid tumors treated with immunotherapy
Presenter: Katerin Rojas Laimito
Session: Poster session 17
703P - Prognostic scores for immunotherapy-based phase one trials (P1T): To GRIm or not to GRIm?
Presenter: Pauline Corbaux
Session: Poster session 17
705P - TIMES: A ctDNA tumor fraction based and externally validated nomogram to predict survival in cancer patients referred for early phase trials
Presenter: Antoine Italiano
Session: Poster session 17
706P - The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway - Safety analysis of the first 126 patients included in the trial
Presenter: Katarina Puco
Session: Poster session 17
707P - Personalised dosing of oral targeted therapies in oncology: The era of therapeutic drug monitoring
Presenter: Maud van der Kleij
Session: Poster session 17